-
Bristol-Myers Squibb's Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New Collaboration
Monday, May 1, 2023 - 11:57am | 493Bristol-Myers Squibb Co (NYSE: BMY) announced topline results from two Breyanzi (lisocabtagene maraleucel) studies: TRANSCEND FL Phase 2 trial in relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001 Phase 1 study relapsed or refractory B-cell non-Hodgkin...
-
Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma
Tuesday, December 14, 2021 - 8:35am | 415Fate Therapeutics Inc (NASDAQ: FATE) showcased interim Phase 1 data from its FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the American Society of Hematology (ASH) Annual Meeting and Exposition. In the second, third, and fourth dose cohorts of...
-
Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients
Tuesday, December 14, 2021 - 7:39am | 364Kite Pharma, a Gilead Science Inc company (NASDAQ: GILD), churned out more data for its CAR-T Yescarta in first-line lymphoma patients. The Company shared the data at the American Society of Hematology (ASH) Annual Meeting & Exposition. In updated results from the...
-
Viracta Therapeutics Posts Data From Lymphoma Trial At ASH Presentation
Monday, December 13, 2021 - 1:13pm | 341Viracta Therapeutics Inc (NASDAQ: VIRX) announced final data from its Phase 1b/2 trial of Nana-val in relapsed/refractory (R/R) EBV+ lymphoma. The data were presented at the 2021 American Society of Hematology (ASH) Annual Meeting. Nana-val was well tolerated and demonstrated...
-
Jazz Posts New Data for ALL/LBL Treatment At ASH 2021 Annual Meeting
Monday, December 13, 2021 - 10:25am | 315Jazz Pharmaceuticals plc (NASDAQ: JAZZ) revealed initial positive results from a Phase 2/3 trial of intramuscular (IM) administration of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). In Cohort 1c...
-
Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings
Monday, December 13, 2021 - 9:55am | 261Roche Holdings AG's (OTC: RHHBY) mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, posted a 60% complete response rate. The data comes from nearly 100 patients with third-line-or-later follicular lymphoma in Phase 1/2...
-
Gilead's Kite Unveils More Data On Yescarta In Second-Line Lymphoma Patients
Monday, December 13, 2021 - 7:18am | 383Kite Pharma, a Gilead Science Inc's Company (NASDAQ: GILD), announced primary analysis results from the ZUMA-7 Phase 3 trial of Yescarta (axicabtagene ciloleucel) as a one-time infusion. The head-to-head study evaluated Yescarta against standard of care (SOC) for...
-
Bristol Myers Reveals Full Data For Breyanzi In Second-Line Lymphoma Setting
Monday, December 13, 2021 - 7:11am | 352Bristol Myers Squibb & Co (NYSE: BMY) released the first disclosure of results from a prespecified interim analysis of Phase 3 TRANSFORM study of Breyanzi (lisocabtagene maraleucel; liso-cel). Breyanzi cut the risk of disease progression, death, and other events by 65% over...
-
TG Therapeutics Shares Plunge After FDA Plans AdComm Meet For Blood Cancer Candidate
Tuesday, November 30, 2021 - 2:07pm | 288TG Therapeutics Inc (NASDAQ: TGTX) shares are falling after FDA notified the Company that it plans to host an Oncologic Drugs Advisory Committee (ODAC) meeting for marketing application regarding ublituximab/ Ukoniq (umbralisib) (U2 combo). U2 Combo application seeks approval for chronic...
-
Affimed's Lymphoma Candidate Shows 100% Objective Response Rate At Highest Dose
Monday, November 22, 2021 - 10:47am | 228Affimed NV (NASDAQ: AFMD) has announced interim clinical results from the investigator-initiated Phase 1/2 study evaluating cbNK cells pre-complexed with Affimed's innate cell engager (ICE) AFM13. Eighteen patients with CD30-positive relapsed or refractory Hodgkin and non-...
-
Soligenix To File US Application For Its Lymphoma Photodynamic Therapy In 2H 2022
Monday, November 1, 2021 - 4:36pm | 216In an SEC filing, Soligenix Inc (NASDAQ: SNGX) disclosed that it cannot file its HyBryte marketing application in the U.S. in 1H of 2022. Citing COVID-19 related disruptions resulting in delays by the commercial active pharmaceutical ingredient manufacturer, the Company cannot...
-
Gilead's Kite Files US Application To Expand Use Of Yescarta In Second-Line Setting
Friday, October 1, 2021 - 8:46am | 308Kite Pharma, a Gilead Science Inc Company (NASDAQ: GILD), has submitted a supplemental marketing application to the FDA for Yescarta (axicabtagene ciloleucel). The application seeks to expand Yescarta's current indication to include adults with relapsed or refractory large...
-
BeiGene's Brukinsa Scores FDA Approval For Marginal Zone Lymphoma
Wednesday, September 15, 2021 - 8:40am | 200The FDA has granted accelerated approval to BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen. The accelerated approval is based on the overall response...
-
Soligenix Stock Moves Higher On US Orphan Drug Tag For T-cell Lymphoma Candidate
Thursday, September 9, 2021 - 9:58am | 250The FDA has granted orphan drug designation to the active ingredient hypericin to treat T-cell lymphoma, extending the target population beyond cutaneous T-cell lymphoma (CTCL) as previously granted. "The FDA's decision to grant and expand our hypericin orphan drug designation...
-
ADC Therapeutics Announces $325M Financing Agreement With HealthCare Royalty
Thursday, August 26, 2021 - 12:27pm | 258ADC Therapeutics SA (NYSE: ADCT) has entered into a royalty purchase agreement with HealthCare Royalty Partners for up to $325 million. ADC Therapeutics will receive $225 million upon closing, with an additional $100 million in potential near-term milestone payments...